Please provide your email address to receive an email when new articles are posted on . ASH issued sickle cell disease research priorities that address seven key focus areas. Topics include end-organ ...
At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma. At ASH ...
Please provide your email address to receive an email when new articles are posted on . American Society of Hematology presented Advocacy Awards to two individuals at this year’s ASH Annual Meeting.
The annual meeting of the American Society of Clinical Oncology drew more than 30,000 attendees to San Diego, and more who participated in the conference virtually, all of them looking to see and hear ...
New results from the Phase II ACCESS trial represent a significant milestone in solving one of transplant medicine’s biggest challenges: finding a donor for every patient in need of a blood stem cell ...
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in ...
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025 – Initial Results from Kite-753, Optimized with ...
New data will further support clinical benefits of ULTOMIRIS® in paroxysmal nocturnal hemoglobinuria and its potential to improve outcomes for pediatric patients with hematopoietic stem cell ...
SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across a range of B-cell malignancies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results